...
首页> 外文期刊>Oncology letters >Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS-13 in patients with lung cancer
【24h】

Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS-13 in patients with lung cancer

机译:ABO血液群与血管血管因子,因子VIII和Adamts-13患者患者肺癌

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Coagulative and fibrinolytic disorders appear to be associated with the development of lung cancer. The aim of the present study was to determine plasma levels of von Willebrand factor (VWF) and a disintegrin and metalloproteinase with a thrombospondin type 1 motif 13 (ADAMTS-13), and factor VIII (FVIII) activity, in association with O and non-O blood groups in patients with lung cancer. Plasma levels of VWF and ADAMTS-13, and FVIII activity were measured in 115 patients with lung cancer and 98 healthy subjects. Phenotyping of the ABO blood groups was also performed for the two groups. Significantly increased VWF levels and FVIII activity, as well as significantly decreased ADAMTS-13 levels, were observed in patients with distant metastasis as compared with those without distant metastasis and the healthy controls. Plasma VWF levels and FVIII activity were significantly increased in subjects with non-O type blood compared with those with type 0 blood in the two groups. However, a significant decrease in ADAMTS-13 levels was observed only in the control group among those with non-O type blood, compared with those with type 0 blood. The results of the present study indicate that increased VWF and decreased ADAMTS-13 levels facilitate the invasiveness and metastasis of lung cancer. Non-O blood groups constitute a risk factor for increased VWF and FVIII in plasma. Continued monitoring of VWF and ADAMTS-13 levels, and of FVIII activity in patients with lung cancer with distinct blood groups may help to minimize the incidence of thrombotic events and improve assessment of disease progression.
机译:凝血性和纤维蛋白溶解障碍似乎与肺癌的发育有关。本研究的目的是确定von Willebrand因子(VWF)的血浆水平和具有血小板气相1型MOTIF13(Adamts-13)的血栓样蛋白的血栓蛋白酶和金属蛋白酶和因子VIII(FVIII)活性,与O和非 - 肺癌患者的血型。在115例肺癌和98名健康受试者中测量了VWF和Adamts-13和FVIII活性的血浆水平。也对两组进行了ABO血型的表型。与没有远离转移和健康对照的人相比,在远处转移的患者中观察到显着增加的VWF水平和FVIII活性,以及​​显着降低的Adamts-13水平。与两组中0型血液的受试者相比,血浆VWF水平和FVIII活性显着增加。然而,与具有0型血液的人相比,仅在非o型血液中的对照组中观察到Adamts-13水平的显着降低。本研究的结果表明,增加的VWF和降低的Adamts-13水平促进了肺癌的侵袭性和转移。非O血液组构成血浆VWF和FVIII增加的危险因素。继续监测VWF和Adamts-13水平,以及具有不同血型肺癌患者的FVIII活性可能有助于最小化血栓形成事件的发生率,并改善对疾病进展的评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号